Rerksuppaphol Sanguansak, Rerksuppaphol Lakkana
Faculty, Department of Paediatrics, Faculty of Medicine, Srinakharinwirot University , Thailand .
Faculty, Department of Preventive Medicine, Faculty of Medicine, Srinakharinwirot University , Thailand .
J Clin Diagn Res. 2015 Mar;9(3):KC01-4. doi: 10.7860/JCDR/2015/11867.5728. Epub 2015 Mar 1.
Hypercholesterolemia is a major risk factor for cardiovascular disease. Not all patients respond well to traditional cholesterol lowering medications. Probiotics have been evaluated for their cholesterol-lowering effects in humans with variable results. This study was performed to evaluate the efficacy of two probiotics in lowering the serum cholesterol of hypercholesterolemic patients.
A randomized double-blind controlled trial was conducted comparing placebo to Lactobacillus acidophilus plus Bifidobacterium bifidum in patients diagnosed with hypercholesterolemia. Placebo or probiotic capsules were taken three times daily for six weeks. Pre- and post-treatment total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) and triglyceride (TG) levels and demographic parameters of the two groups were compared. From a total of 70 participants, 64 completed the assigned treatment (31 in probiotics group and 33 in the control group).The two treatment groups were matched for age, sex, weight, height, BMI, waist and hip circumferences, and blood pressure.
Baseline evaluation revealed no difference between the probiotics group and control group levels of TC, HDL-C, LDL-C and TG. TC levels in the probiotics group decreased during treatment (237.2 vs. 212.7 mg/dL, p<0.05). TC and LDL-C levels in the control group increased significantly from their baseline levels during treatment. TC (212.7 vs 252.8 mg/dL, p<0.001), HDL-C (52.0 vs 59.1 mg/dL, p=0.04) and LDL-C (153.9 vs 182.1 mg/dL, p<0.01) levels in the probiotics group were significantly lower at the end of treatment than the corresponding levels in the control group.
A combination of Lactobacillus acidophilus and Bifidobacterium bifidum decreased serum total cholesterol, LDL-cholesterol and HDL-cholesterol levels in hypercholesterolemic patients over a six week period. There was no effect on serum triglyceride or fasting blood glucose levels.
高胆固醇血症是心血管疾病的主要危险因素。并非所有患者对传统的降胆固醇药物反应良好。已对益生菌在人类中的降胆固醇作用进行了评估,结果各异。本研究旨在评估两种益生菌降低高胆固醇血症患者血清胆固醇的疗效。
进行了一项随机双盲对照试验,将安慰剂与嗜酸乳杆菌加双歧杆菌用于诊断为高胆固醇血症的患者。安慰剂或益生菌胶囊每日服用三次,持续六周。比较了两组治疗前后的总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)水平以及人口统计学参数。在总共70名参与者中,64人完成了指定治疗(益生菌组31人,对照组33人)。两个治疗组在年龄、性别、体重、身高、BMI、腰围和臀围以及血压方面相匹配。
基线评估显示益生菌组和对照组的TC、HDL-C、LDL-C和TG水平无差异。益生菌组的TC水平在治疗期间下降(237.2对212.7mg/dL,p<0.05)。对照组的TC和LDL-C水平在治疗期间从基线水平显著升高。治疗结束时,益生菌组的TC(212.7对252.8mg/dL,p<0.001)、HDL-C(52.0对59.1mg/dL,p=0.04)和LDL-C(153.9对182.1mg/dL,p<0.01)水平显著低于对照组的相应水平。
嗜酸乳杆菌和双歧杆菌的组合在六周内降低了高胆固醇血症患者的血清总胆固醇、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平。对血清甘油三酯或空腹血糖水平无影响。